Home > Insider Trading > Filing (0001562180-24-000636)

Filing Details

Accession Number:: 0001562180-24-000636
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-25 18:24:43
Reporting Period:: 2024-01-23

Accepted Time:: 2024-01-25 18:24:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1314102	Eyepoint Pharmaceuticals Inc.	EYPT	Laboratory Analytical Instruments (3826)	262774444

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1450485	Nancy Lurker	C/O Eyepoint Pharmaceuticals, Inc. 480 Pleasant Street Watertown MA 02472	Executive Vice Chair	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-01-23	5,044	$24.97	165,397	No	4	S	Direct
Common Stock	Disposition	2024-01-24	29,956	$24.98	135,441	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-01-24	112,700	$0.00	112,700	$3.26
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-01-24	112,700	$0.00	112,700	$3.26

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
338,100		2033-01-05	No	4	G	Direct
112,700		2033-01-05	No	4	G	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	52,208	Indirect	By Family Trust

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.24. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
On January 24, 2024, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on January 6, 2023 and was exercisable for 112,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 112,700 shares of Common Stock of the Company.
The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.